Take the Diabetes Health Pump Survey
Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Latest
Popular
Top Rated

Latest Type 1 Issues Articles

Reduced Insulin May Prevent Exercise-Related Hypoglycemia
New Website Aims at Type 1 Teens
If someone needs to restrict their protein intake because of kidney damage, is it safe to do a low carb diet?
How Crunch Time Affects Kids’ Health
An Interview With My Husband, Rick
Living With Type 1 Diabetes
Is it dangerous to continually have low-grade ketone levels in your blood?
What meds do you recommend to control elevated cholesterol?
Five Simple Ways to Lower Your Blood Sugar
We’re Not Bad, We’re Human
Diabetes Health Reference Charts
Syringes Reference Guide (PDF)
Insulin Pumps Reference Guide (PDF)
Lancing Devices Reference Guide (PDF)
Infusion Sets Reference Guide (PDF)
Blood Glucose Meters Reference Guide (PDF)
Insulin Pen Needles Reference Guide (PDF)
Lancing Devices Reference Guide (PDF)
Continuous Glucose Monitors Reference Guide (PDF)
Fast Acting Glucose Reference Guide (PDF)
Insulin Reference Guide (PDF)
See All Charts…
Type 1 Issues Archives
Browse the Type 1 Issues Archives
Subscribe to the Community RSS Feed
Print | Email | Share | Comments (0)

Clinical Trial Aims to Lower Insulin Requirements


Jun 1, 1997

Ergo Science Corporation, located in Charlestown, Massachusetts, has initiated a human clinical trial for FDA approval of its Ergoset tablets. The tablets are intended to reduce insulin requirements for people with type 2 diabetes who are on insulin.

The object of the trial is to lower BGs and daily insulin requirements of people with type 2 whose BGs have not been sufficiently controlled on oral hypoglycemic agents and insulin. This type of patient represents approximately three million of the seven million type 2s who receive treatment for their diabetes.

Efficient use of insulin for these patients is important as excess insulin in the bloodstream has been associated with cardiovascular disease.

The phase III human clinical trial of Ergoset for FDA approval demonstrated "significant and meaningful results in people with type 2 diabetes," according to a company press release.

Categories: Diabetes, Events, Insulin, Type 1 Issues, Type 2 Issues

Donate to Diabetes Health

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - Jun 1, 1997

©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.